Aytu Biopharma (AYTU) Deferred Taxes (2014)
Aytu Biopharma's (AYTU) quarterly Deferred Taxes came in at -$1.0 in Q4 2014, up 100.0% quarter-over-quarter from -$23909.0 in Q3 2014.
Powered by 
Analysis
Aytu Biopharma (AYTU) Deferred Taxes (2014) Analysis & Trends
Aytu Biopharma (AYTU) has reported Deferred Taxes for 1 consecutive years, with -$1.0 the latest figure, recorded in Q4 2014.
- On a quarterly basis, Deferred Taxes changed N/A year-over-year to -$1.0 in Q4 2014; TTM through Dec 2015 was -$1.0, a N/A change from a year earlier, with the FY2015 full-year figure at -$23910.0, up 97.06% from the prior year.
- Deferred Taxes was -$1.0 for Q4 2014 at Aytu Biopharma, up from -$23909.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at -$1.0 in Q4 2014 and troughed at -$23909.0 in Q3 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -1.32 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 115.62 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 25.70 Mn |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | - |